Zidovudine impairs immunological recovery on first-line antiretroviral therapy: collaborative analysis of cohort studies in southern Africa

Wandeler, Gilles; Gsponer, Thomas; Mulenga, Lloyd; Garone, Daniela; Wood, Robin; Maskew, Mhairi; Prozesky, Hans; Hoffmann, Christopher; Ehmer, Jochen; Dickinson, Diana; Davies, Mary-Ann; Egger, Matthias; Keiser, Olivia (2013). Zidovudine impairs immunological recovery on first-line antiretroviral therapy: collaborative analysis of cohort studies in southern Africa. AIDS, 27(14), pp. 2225-2232. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/QAD.0b013e328362d887

	Text 00002030-201309100-00009.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (488kB) | Request a copy
Preview	Text Wandeler AIDS 2013_manuscript.pdf - Accepted Version Available under License Publisher holds Copyright. Download (631kB) | Preview

OBJECTIVES
Zidovudine (ZDV) is recommended for first-line antiretroviral therapy (ART) in resource-limited settings. ZDV may, however, lead to anemia and impaired immunological response. We compared CD4+ cell counts over 5 years between patients starting ART with and without ZDV in southern Africa.

DESIGN
Cohort study.

METHODS
Patients aged at least 16 years who started first-line ART in South Africa, Botswana, Zambia, or Lesotho were included. We used linear mixed-effect models to compare CD4+ cell count trajectories between patients on ZDV-containing regimens and patients on other regimens, censoring follow-up at first treatment change. Impaired immunological recovery, defined as a CD4+ cell count below 100 cells/μl at 1 year, was assessed in logistic regression. Analyses were adjusted for baseline CD4+ cell count and hemoglobin level, age, sex, type of regimen, viral load monitoring, and calendar year.

RESULTS
A total of 72,597 patients starting ART, including 19,758 (27.2%) on ZDV, were analyzed. Patients on ZDV had higher CD4+ cell counts (150 vs.128 cells/μl) and hemoglobin level (12.0 vs. 11.0 g/dl) at baseline, and were less likely to be women than those on other regimens. Adjusted differences in CD4+ cell counts between regimens containing and not containing ZDV were -16 cells/μl [95% confidence interval (CI) -18 to -14] at 1 year and -56 cells/μl (95% CI -59 to -52) at 5 years. Impaired immunological recovery was more likely with ZDV compared to other regimens (odds ratio 1.40, 95% CI 1.22-1.61).

CONCLUSION
In southern Africa, ZDV is associated with inferior immunological recovery compared to other backbones. Replacing ZDV with another nucleoside reverse transcriptase inhibitor could avoid unnecessary switches to second-line ART.

Interest & Impact

Downloads

143 since deposited on 16 Jan 2014
3 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item